Cosentyx
E584151
Cosentyx is a biologic medication (secukinumab) used to treat autoimmune inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Cosentyx canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6311254 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Cosentyx Context triple: [Novartis, notableDrug, Cosentyx]
-
A.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
D.
Dupixent
Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
-
E.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Cosentyx Target entity description: Cosentyx is a biologic medication (secukinumab) used to treat autoimmune inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
-
A.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
D.
Dupixent
Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
-
E.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
pharmaceutical drug ⓘ |
| affectsSystem | immune system ⓘ |
| bindsTo | IL-17A cytokine ⓘ |
| canBeSelfAdministered | true ⓘ |
| hasApprovalYear | 2015 ⓘ |
| hasATCCode | L04AC10 ⓘ |
| hasBrandOwner | Novartis Pharmaceuticals Corporation NERFINISHED ⓘ |
| hasCommonAdverseEffect |
diarrhea
ⓘ
headache ⓘ nasopharyngitis ⓘ upper respiratory tract infection ⓘ |
| hasContraindication | serious active infection ⓘ |
| hasDosageForm |
prefilled autoinjector pen
ⓘ
prefilled syringe ⓘ solution for injection ⓘ |
| hasDrugClass |
immunosuppressive agent
ⓘ
monoclonal antibody ⓘ |
| hasGenericName | secukinumab NERFINISHED ⓘ |
| hasIndication |
active ankylosing spondylitis
ⓘ
active non-radiographic axial spondyloarthritis with objective signs of inflammation ⓘ active psoriatic arthritis ⓘ enthesitis-related arthritis in pediatric patients ⓘ moderate-to-severe plaque psoriasis in adults ⓘ moderate-to-severe plaque psoriasis in pediatric patients ⓘ plaque psoriasis in pediatric patients aged 6 years and older ⓘ |
| hasLoadingDoseRegimen | weekly injections for first 5 weeks in some indications ⓘ |
| hasMaintenanceDoseRegimen | every 4 weeks ⓘ |
| hasMechanismOfAction | inhibits IL-17A cytokine ⓘ |
| hasMolecularType | human monoclonal antibody ⓘ |
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| hasSeriousAdverseEffect | increased risk of infections ⓘ |
| hasWarning | may exacerbate inflammatory bowel disease ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isAdministeredTo |
adults
ⓘ
children ⓘ |
| isApprovedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| isIndicatedFor | chronic systemic inflammatory conditions ⓘ |
| isManufacturedBy | Novartis NERFINISHED ⓘ |
| isUsedFor |
ankylosing spondylitis
ⓘ
autoimmune inflammatory diseases ⓘ non-radiographic axial spondyloarthritis ⓘ plaque psoriasis ⓘ psoriasis ⓘ psoriatic arthritis ⓘ |
| reduces | inflammatory response mediated by IL-17A ⓘ |
| targets | interleukin-17A ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Cosentyx Description of subject: Cosentyx is a biologic medication (secukinumab) used to treat autoimmune inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.